Lack of Clinical Relevance of ANA and ASMA Positivity in Patients with Liver Transplantation without a History of Autoimmune Diseases

Table 3

ASMA positivity (≥1 : 40) according to different risk factors during the study period.

		ASMA positivity (≥1 : 40)
	Total number of patients	0	6	12
Gender
(i) Male	76	9 (11.8)	12 (15.8)	15 (19.7)
(ii) Female	38	4 (10.5)	7 (18.4)	4 (10.5)
		0.8	0.7	0.2
Cause of transplantation
(i) HBV	39	1 (2.5)	5 (12.8)	3 (7.7)
(ii) HCV	57	11 (19.3)	10 (17.5)	11 (19.3)
(iii) Other	18	1 (5.5)	4 (22.2)	5 (27.8)
		0.03	0.6	0.1
HCC at the time of transplantation
(i) No	74	5 (6.7)	13 (17.6)	12 (16.2)
(ii) Yes	40	8 (20)	6 (15)	7 (17.5)
		0.03	0.7	0.8
Early rejection
(i) No	87	12 (13.8)	12 (13.8)	13 (14.9)
(ii) Yes	27	1 (3.7)	7 (25.9)	6 (22.2)
		0.1	0.1	0.4
Time from transplantation
(i) >3 months–1 year	11	1 (9.1)	2 (18.2)	1 (9.1)
(ii) >1 year–5 years	27	5 (18.5)	7 (25.9)	7 (25.9)
(iii) >5 years–10 years	26	3 (11.5)	2 (7.7)	3 (11.5)
(iv) >10 years	50	4 (8)	8 (16)	8 (16)
		0.5	0.3	0.4
Age group at 0
(i) ≤50 years	15	1 (6.7)	3 (20)	1 (6.7)
(ii) >50–60 years	34	4 (11.7)	3 (8.8)	4 (11.7)
(iii) >60 years	65	8 (12.3)	13 (20)	14 (21.5)
		0.8	0.3	0.2
Therapy at the time of the study (constant at 0-6 and 12)
(i) Cyclosporine	32	2 (6.2)	4 (12.5)	7 (21.9)
(ii) FK	55	8 (14.5)	10 (18.2)	8 (14.5)
(iii) Mycophenolate	12	1 (8.3)	1 (8.3)	0 (0)
(iv) Everolimus	15	2 (13.3)	4 (26.7)	4 (26.7)
		0.6	0.5	0.2